GlassScriptPhysician profile
Ryan Paul Matteson
NPI 1912474479
$1,222.63
in general payments reported to CMS, 2019-2025
28 companies · $83.42 in 2025
The $83.42 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $126 · 2022: $416 · 2023: $535 · 2024: $63.13 · 2025: $83.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $681.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $681.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $290.30 | 2022-2024 | Farxiga, Breztri, Evusheld |
| Abbvie INC. | $181.21 | 2022-2023 | |
| Novo Nordisk INC | $110.31 | 2021-2023 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.66 | 2022 | |
| Cranial Technologies, INC | $55.51 | 2021-2025 | Doc Band |
| Takeda Pharmaceuticals U.S.A., INC. | $54.87 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $49.99 | 2024 | |
| Lilly USA, LLC | $44.71 | 2021-2023 | Emgality, Reyvow |
| Teva Pharmaceuticals USA, INC. | $39.10 | 2023 | Austedo Xr |
| Pfizer INC. | $26.94 | 2023 | |
| Phadia US INC. | $22.56 | 2025 | Immunocap |
| Acadia Pharmaceuticals INC | $21.97 | 2025 | Daybue |
| Astellas Pharma US INC | $21.83 | 2023 | Veozah |
| Curonix LLC | $18.57 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.59 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $17.30 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $17.17 | 2023 | |
| Amarin Pharma, INC. | $17.14 | 2022 | |
| Glaxosmithkline, LLC. | $17.02 | 2022 | |
| Tris Pharma INC | $16.63 | 2023 | Dyanavel Xr |
| Biohaven Pharmaceuticals, INC. | $16.15 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.86 | 2021 | |
| Kaleo, INC. | $15.40 | 2022 | |
| Hologic Sales and Service, LLC | $14.07 | 2021 | |
| Genentech USA, INC. | $13.82 | 2021 | |
| Mannkind Corporation | $13.75 | 2022 | |
| Supernus Pharmaceuticals, INC. | $13.70 | 2022 | |
| Daiichi Sankyo INC. | $13.50 | 2023 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Matteson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.